Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 14, 2026 16:05 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences to Report Second Quarter 2026 Financial Results on August 10, 2026

FREMONT, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in Precision Proteomics dedicated to enabling the earliest detection of disease, today announced...
July 13, 2026 12:51 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences 联合多所顶尖研究型大学推出全国性研究计划，推进神经退行性疾病血液生物标志物相关研究

这项全国性研究计划将利用 Alamar Biosciences 的 NULISAseq™ Neuro 220 检测试剂盒，对 10,000 名阿尔茨海默病及相关痴呆症 (ADRD) 受试者提供的约 21,000 万份血浆样本开展图谱分析。生成的数据集将对外开放，可通过 National Alzheimer’s Coordinating Center (美国国家阿尔茨海默病协调中心)...
July 13, 2026 12:51 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences 與多間頂尖研究大學合作啟動全國計劃，旨在推動神經退行性疾病相關的血漿生物標記研究

這項全國計劃會採用 Alamar Biosciences 的 NULISAseq™ Neuro 220 多重檢測組合試劑盒，分析來自 10,000 名阿茲海默症及相關認知障礙症 (ADRD) 參與者約 21,000 份的血漿樣本。研究所得的數據集將全面開放，經由 National Alzheimer’s Coordinating Center...
July 13, 2026 02:30 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

National-scale initiative will profile ~21,000 plasma samples from 10,000 Alzheimer’s Disease and Related Dementias (ADRD) participants using Alamar Biosciences' NULISAseq™ Neuro 220 panel. Resulting...
July 13, 2026 02:30 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences Partners with Leading Research Universities to Launch National Initiative Advancing Blood-Based Biomarkers for Neurodegenerative Diseases

Fremont, CA, July 13, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to advancing the early detection of disease, today announced a...
July 10, 2026 19:24 ET | Source: Alamar Biosciences, Inc.

AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据，彰显阿尔茨海默病血液生物标志物分析领域的进展

加利福尼亚州弗里蒙特, July 11, 2026 (GLOBE NEWSWIRE) -- 致力于实现疾病最早期检测的精准蛋白质组学领域领导者 Alamar Biosciences, Inc. (Nasdaq: ALMR) 今日宣布，其 NULISA™ 平台将在 7 月 12 日至 15 日于伦敦举行的阿尔茨海默病协会国际会议 (AAIC) 上，于逾 140...
July 10, 2026 19:24 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences 的 NULISA 數據將於 AAIC 2026 上超過 140 場科學簡報會中亮相，突顯基於血液的阿茲海默症生物標記剖析之最新進展

加州佛利蒙, July 11, 2026 (GLOBE NEWSWIRE) -- 致力推動疾病最早期檢測的精準蛋白質體學領導企業 Alamar Biosciences, Inc. (Nasdaq: ALMR) 今天宣佈，其 NULISA™ 平台將於 7 月 12 日至 15 日在倫敦舉行的阿茲海默症協會國際會議 (AAIC) 上，以超過 140...
July 10, 2026 06:11 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

FREMONT, Calif., July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced...
July 10, 2026 06:11 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling

Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced that...
July 07, 2026 21:55 ET | Source: Alamar Biosciences, Inc.

Alamar Biosciences 推出首款血液多重免疫檢測，用於檢測 eMTBR-Tau，它是阿茲海默症研究中最重要生物標記之一

eMTBR-Tau 是一種非侵入性的血液 tau 蛋白纏結負荷測量方法，該纏結是阿茲海默症中與疾病進展和認知能力衰退相關的核心病理特徵 eMTBR-Tau 免疫檢測現已納入 NULISAseq™ Neuro 220 檢測組合，亦可透過 Technology Access Program 以單重檢測形式提供 Alamar 將於 AAIC 2026 工作坊發表相關數據加州佛利蒙, July ...